X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (23848) 23848
Newsletter (495) 495
Magazine Article (188) 188
Newspaper Article (51) 51
Book Chapter (16) 16
Transcript (16) 16
Book / eBook (8) 8
Conference Proceeding (6) 6
Publication (4) 4
Reference (2) 2
Book Review (1) 1
Paper (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (19560) 19560
staphylococcal infections - drug therapy (14782) 14782
male (10070) 10070
female (9545) 9545
anti-bacterial agents - therapeutic use (7662) 7662
staphylococcal infections - microbiology (7038) 7038
staphylococcus aureus (5954) 5954
adult (5831) 5831
middle aged (5773) 5773
staphylococcus aureus - drug effects (5040) 5040
animals (4916) 4916
aged (4527) 4527
infectious diseases (4413) 4413
microbiology (4322) 4322
microbial sensitivity tests (3979) 3979
anti-bacterial agents - pharmacology (3699) 3699
methicillin resistance (3199) 3199
staphylococcal infections (3102) 3102
staphylococcus aureus - isolation & purification (2887) 2887
infections (2878) 2878
adolescent (2820) 2820
staphylococcal infections - epidemiology (2810) 2810
antibiotics (2762) 2762
child (2680) 2680
staphylococcal infections - diagnosis (2673) 2673
pharmacology & pharmacy (2536) 2536
health aspects (2529) 2529
treatment outcome (2493) 2493
anti-bacterial agents - administration & dosage (2191) 2191
methicillin-resistant staphylococcus aureus - drug effects (2166) 2166
vancomycin (2047) 2047
retrospective studies (2025) 2025
infection (2020) 2020
risk factors (1993) 1993
staphylococcus aureus infections (1981) 1981
drug resistance in microorganisms (1973) 1973
staphylococcal infections - complications (1940) 1940
methicillin-resistant staphylococcus aureus - isolation & purification (1923) 1923
mice (1859) 1859
child, preschool (1845) 1845
methicillin-resistant staphylococcus aureus (1816) 1816
infant (1807) 1807
vancomycin - therapeutic use (1698) 1698
aged, 80 and over (1688) 1688
surgery (1643) 1643
mrsa (1601) 1601
staphylococcal infections - etiology (1596) 1596
staphylococcus infections (1560) 1560
research (1548) 1548
bacteremia (1508) 1508
bacteria (1468) 1468
drug resistance (1418) 1418
staphylococcal infections - prevention & control (1401) 1401
epidemiology (1399) 1399
immunology (1372) 1372
medicine, general & internal (1260) 1260
care and treatment (1258) 1258
prevalence (1255) 1255
infant, newborn (1252) 1252
analysis (1236) 1236
streptococcal infections - drug therapy (1232) 1232
drug resistance, microbial (1172) 1172
cross infection - microbiology (1159) 1159
endocarditis, bacterial - drug therapy (1159) 1159
mortality (1135) 1135
drug therapy, combination (1131) 1131
drug therapy (1126) 1126
bacteremia - drug therapy (1108) 1108
staphylococcus - drug effects (1090) 1090
cross infection - drug therapy (1088) 1088
drug resistance, bacterial (1078) 1078
bacteremia - microbiology (1067) 1067
pediatrics (1058) 1058
time factors (1043) 1043
research article (1035) 1035
nosocomial infections (1018) 1018
hospitals (1010) 1010
disease models, animal (1008) 1008
therapy (992) 992
endocarditis (975) 975
staphylococcus aureus - genetics (972) 972
methicillin (965) 965
prospective studies (964) 964
diagnosis (955) 955
staphylococcal skin infections - drug therapy (945) 945
young adult (945) 945
staphylococcal infections - therapy (943) 943
skin (927) 927
resistant staphylococcus-aureus (912) 912
methicillin-resistant (911) 911
biochemical phenomena, metabolism, and nutrition (906) 906
antibacterial agents (897) 897
vancomycin - pharmacology (878) 878
management (861) 861
cross infection - epidemiology (849) 849
children (844) 844
rabbits (832) 832
pneumonia (829) 829
medicine (823) 823
medical research (817) 817
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (21638) 21638
Russian (674) 674
French (634) 634
German (607) 607
Japanese (527) 527
Spanish (375) 375
Italian (171) 171
Polish (140) 140
Portuguese (101) 101
Chinese (75) 75
Dutch (75) 75
Danish (65) 65
Romanian (40) 40
Turkish (39) 39
Czech (38) 38
Norwegian (35) 35
Ukrainian (31) 31
Swedish (25) 25
Hungarian (19) 19
Hebrew (18) 18
Finnish (15) 15
Croatian (12) 12
Serbian (7) 7
Bulgarian (6) 6
Korean (3) 3
Lithuanian (3) 3
Slovak (3) 3
Icelandic (2) 2
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Burns, ISSN 0305-4179, 2017, Volume 43, Issue 3, pp. 642 - 653
Highlights • Burn depth/agent increases risk of developing an infection. • Infections found folliculitis, burn wound, urinary tract, pneumonia, CVC and bloodstream... 
Critical Care | Nosocomial infection | Burn wound infection | Pneumonia | Urinary tract infection | Health care related infection | Burns | URINARY-TRACT-INFECTION | MORTALITY | SURGERY | RISK-FACTORS | DERMATOLOGY | REPLACEMENT | BACTERIOLOGY | CATHETERS | INTENSIVE-CARE-UNIT | SURVEILLANCE | ASSOCIATION | BLOOD-STREAM INFECTIONS | CRITICAL CARE MEDICINE | Escherichia coli | Humans | Middle Aged | Child, Preschool | Male | Young Adult | Folliculitis - epidemiology | Aged, 80 and over | Urinary Tract Infections - microbiology | Catheter-Related Infections - epidemiology | Child | Infant, Newborn | Staphylococcus aureus | Escherichia coli Infections - drug therapy | Bacteremia - drug therapy | Pseudomonas Infections - microbiology | Wound Infection - epidemiology | Catheter-Related Infections - drug therapy | Drug Resistance, Microbial | Escherichia coli Infections - epidemiology | Acinetobacter baumannii | Catheter-Related Infections - microbiology | Adolescent | Bacteremia - epidemiology | Infant | Bacteremia - microbiology | Cephalosporins - therapeutic use | Anti-Bacterial Agents - therapeutic use | Klebsiella Infections - epidemiology | Adult | Female | Pseudomonas aeruginosa | Staphylococcal Infections - microbiology | Wound Infection - drug therapy | Acinetobacter Infections - microbiology | Staphylococcal Infections - drug therapy | Colombia - epidemiology | Klebsiella Infections - drug therapy | Central Venous Catheters | Pneumonia - epidemiology | Pseudomonas Infections - drug therapy | Acinetobacter Infections - drug therapy | Escherichia coli Infections - microbiology | Folliculitis - microbiology | Pneumonia - microbiology | Klebsiella Infections - microbiology | Oxacillin - therapeutic use | Burns - epidemiology | Urinary Tract Infections - drug therapy | Urinary Tract Infections - epidemiology | Pneumonia - drug therapy | Staphylococcal Infections - epidemiology | Pseudomonas Infections - epidemiology | Acinetobacter Infections - epidemiology | Wound Infection - microbiology | Aged | Folliculitis - drug therapy | Klebsiella pneumoniae | Development and progression | Burns and scalds | Surgery, Plastic | Health aspects | Staphylococcus aureus infections | Analysis | Bacterial pneumonia | Mortality | Urinary tract infections | Bacteria | Disease susceptibility | Antibacterial agents
Journal Article
American journal of respiratory and critical care medicine, ISSN 1535-4970, 2016, Volume 193, Issue 5, pp. 504 - 515
Rationale: Cystic fibrosis (CF) is characterized by early structural lung disease caused by pulmonary infections... 
Healthy controls | Cystic fibrosis | Microbiota | Nasopharynx | Longitudinal | microbiota | SMALL-COLONY VARIANTS | CARRIAGE | HAEMOPHILUS-INFLUENZAE | COMMUNITIES | CHILDREN | STREPTOCOCCUS-PNEUMONIAE | INHIBITION | RESPIRATORY SYSTEM | cystic fibrosis | INFLAMMATION | LUNG-DISEASE | STAPHYLOCOCCUS-AUREUS | longitudinal | nasopharynx | healthy controls | CRITICAL CARE MEDICINE | Carrier State - epidemiology | Streptococcus mitis - genetics | Prospective Studies | Humans | Corynebacterium Infections - epidemiology | Carrier State - microbiology | Haemophilus Infections - epidemiology | Infant | Male | Corynebacterium Infections - microbiology | Case-Control Studies | Anti-Bacterial Agents - therapeutic use | Enterobacteriaceae Infections - epidemiology | Female | Staphylococcal Infections - microbiology | Nasopharynx - microbiology | Real-Time Polymerase Chain Reaction | Burkholderia Infections - microbiology | Haemophilus Infections - drug therapy | Infant, Newborn | Staphylococcus aureus - genetics | Moraxellaceae Infections - epidemiology | Streptococcal Infections - microbiology | Burkholderia - genetics | Staphylococcal Infections - drug therapy | Burkholderia Infections - epidemiology | Cystic Fibrosis - microbiology | Enterobacteriaceae Infections - microbiology | Enterobacteriaceae - genetics | Moraxellaceae Infections - microbiology | Streptococcal Infections - epidemiology | Haemophilus influenzae - genetics | Corynebacterium - genetics | Cystic Fibrosis - epidemiology | Moraxellaceae Infections - drug therapy | DNA, Bacterial - genetics | Staphylococcal Infections - epidemiology | Corynebacterium Infections - drug therapy | Microbiota - genetics | Burkholderia Infections - drug therapy | Haemophilus Infections - microbiology | RNA, Ribosomal, 16S - genetics | Streptococcal Infections - drug therapy | Moraxella - genetics | Cohort Studies | Enterobacteriaceae Infections - drug therapy
Journal Article
The Journal of infectious diseases, ISSN 1537-6613, 2014, Volume 210, Issue 9, pp. 1357 - 1366
Background. Limitations in treatment of biofilm-associated bacterial infections are often due to subpopulation of persistent bacteria (persisters... 
Biofilms | Antibiotics | Escherichia coli | pH | Bacteria | Aminoglycosides | Pseudomonas aeruginosa | Infections | Basic amino acids | Staphylococcus aureus | aminoglycoside | persister | catheter-related infections | biofilm | proton motive force | DIAGNOSIS | INFECTIOUS DISEASES | INFECTIONS | MANAGEMENT | TOLERANCE | SUSCEPTIBILITY | MICROBIOLOGY | IMMUNOLOGY | ANTIBIOTIC-LOCK THERAPY | GENTAMICIN | PSEUDOMONAS-AERUGINOSA | L-ARGININE | GROWTH | Escherichia coli Infections - prevention & control | Central Venous Catheters - microbiology | Escherichia coli - drug effects | Gentamicins - administration & dosage | Catheter-Related Infections - prevention & control | Pseudomonas Infections - prevention & control | Arginine - administration & dosage | Gentamicins - pharmacology | Drug Therapy, Combination | Biofilms - drug effects | Escherichia coli Infections - drug therapy | Staphylococcal Infections - drug therapy | Pseudomonas Infections - drug therapy | Rats | Central Venous Catheters - adverse effects | Pseudomonas aeruginosa - drug effects | Catheter-Related Infections - drug therapy | Drug Synergism | Animals | Arginine - pharmacology | Staphylococcal Infections - prevention & control | Anti-Bacterial Agents - pharmacology | In Vitro Techniques | Staphylococcus aureus - drug effects | Hydrogen-Ion Concentration | Health aspects | Research | Index Medicus | Abridged Index Medicus | Biofilms/drug effects | Gentamicins/administration & dosage | Anti-Bacterial Agents/pharmacology | Staphylococcal Infections/drug therapy | Arginine/administration & dosage | Life Sciences | Escherichia coli Infections/drug therapy | Staphylococcus aureus/drug effects | Gentamicins/pharmacology | Catheter-Related Infections/prevention & control | Pseudomonas aeruginosa/drug effects | Staphylococcal Infections/prevention & control | Catheter-Related Infections/drug therapy | Central Venous Catheters/microbiology | Escherichia coli/drug effects | Bacteriology | Microbiology and Parasitology | Central Venous Catheters/adverse effects | Arginine/pharmacology | Pseudomonas Infections/prevention & control | Escherichia coli Infections/prevention & control | Pseudomonas Infections/drug therapy
Journal Article
Clinical infectious diseases, ISSN 1537-6591, 2015, Volume 61, Issue suppl 2, pp. S69 - S78
Skin and soft-tissue infections (SSTIs) are an important cause of morbidity and mortality among hospitalized patients and a major therapeutic challenge for clinicians... 
telavancin | necrotizing infections | skin infections | cellulitis | soft-tissue infections | UNITED-STATES | INFECTIOUS DISEASES | HOSPITALIZED-PATIENTS | RISK-FACTORS | NECROTIZING FASCIITIS | CARE-ASSOCIATED INFECTIONS | MICROBIOLOGY | IMMUNOLOGY | COMPLICATED SKIN | STREPTOCOCCAL INFECTIONS | STAPHYLOCOCCUS-AUREUS INFECTIONS | SURGICAL SITE INFECTION | EPIDEMIOLOGY | Skin Diseases, Bacterial - microbiology | Humans | Skin Diseases, Bacterial - drug therapy | Oxazolidinones - therapeutic use | Gram-Negative Bacterial Infections - microbiology | Microbial Sensitivity Tests | Anti-Bacterial Agents - therapeutic use | Skin Diseases, Bacterial - epidemiology | Gram-Positive Bacterial Infections - microbiology | Soft Tissue Infections - drug therapy | Staphylococcal Infections - microbiology | Daptomycin - therapeutic use | Staphylococcal Infections - drug therapy | Methicillin-Resistant Staphylococcus aureus - drug effects | Gram-Negative Bacterial Infections - drug therapy | Clinical Trials as Topic | Soft Tissue Infections - epidemiology | Gram-Positive Bacterial Infections - epidemiology | Daptomycin - pharmacology | Soft Tissue Infections - microbiology | Staphylococcal Infections - epidemiology | Oxazolidinones - pharmacology | Gram-Negative Bacterial Infections - epidemiology | Anti-Bacterial Agents - pharmacology | North America - epidemiology | Aminoglycosides - pharmacology | Gram-Positive Bacterial Infections - drug therapy | Aminoglycosides - therapeutic use
Journal Article
American journal of respiratory and critical care medicine, ISSN 1535-4970, 2019, Volume 200, Issue 7, pp. e45 - e67
...: The panel addressed 16 specific areas for recommendations spanning questions of diagnostic testing, determination of site of care, selection of initial empiric antibiotic therapy, and subsequent management decisions... 
LOW-RISK PATIENTS | SUSPECTED PNEUMOCOCCAL PNEUMONIA | VENTILATOR-ASSOCIATED PNEUMONIA | CARE-ASSOCIATED PNEUMONIA | BETA-LACTAM MONOTHERAPY | community-acquired pneumonia | RESISTANT STAPHYLOCOCCUS-AUREUS | SPUTUM GRAM STAIN | MILD-TO-MODERATE | pneumonia | RESPIRATORY SYSTEM | CRITICALLY-ILL PATIENTS | patient management | HIGH-DOSAGE AMOXICILLIN | CRITICAL CARE MEDICINE | Community-Acquired Infections - diagnosis | Culture Techniques | United States | Humans | Pneumonia, Pneumococcal - diagnosis | Haemophilus Infections - diagnosis | Anti-Bacterial Agents - therapeutic use | Community-Acquired Infections - drug therapy | Adult | Haemophilus Infections - metabolism | Drug Therapy, Combination | Haemophilus Infections - drug therapy | Pneumonia, Mycoplasma - metabolism | Severity of Illness Index | Chlamydophila Infections - drug therapy | Blood Culture | Chlamydophila Infections - metabolism | Legionellosis - diagnosis | Hospitalization | Legionellosis - drug therapy | Pneumonia, Bacterial - diagnosis | Ambulatory Care | Moraxellaceae Infections - drug therapy | Chlamydophila Infections - diagnosis | Pneumonia, Pneumococcal - metabolism | Antigens, Bacterial - urine | Pneumonia, Staphylococcal - drug therapy | Moraxellaceae Infections - metabolism | Pneumonia, Staphylococcal - diagnosis | Pneumonia, Staphylococcal - metabolism | Sputum | Pneumonia, Bacterial - drug therapy | Legionellosis - metabolism | Pneumonia, Pneumococcal - drug therapy | Radiography, Thoracic | Moraxellaceae Infections - diagnosis | Macrolides - therapeutic use | beta-Lactams - therapeutic use | Pneumonia, Mycoplasma - diagnosis | Pneumonia, Mycoplasma - drug therapy
Journal Article
PloS one, ISSN 1932-6203, 2014, Volume 9, Issue 3, p. e91713
...) in a network of community hospitals and 2) determine risk factors for inappropriate therapy for bloodstream infections in community hospitals... 
METHICILLIN-RESISTANT | MORTALITY | METAANALYSIS | MULTIDISCIPLINARY SCIENCES | ANTIMICROBIAL TREATMENT | VALIDATION | PREVENTION | STAPHYLOCOCCUS-AUREUS BACTEREMIA | ENDOCARDITIS | EPIDEMIOLOGY | SEVERITY | United States - epidemiology | Pseudomonas aeruginosa - isolation & purification | Community-Acquired Infections - epidemiology | Escherichia coli - drug effects | Humans | Middle Aged | Pseudomonas aeruginosa - growth & development | Drug Resistance, Bacterial | Male | Hospitals, Community | Bacteremia - microbiology | Gram-Negative Bacterial Infections - microbiology | Microbial Sensitivity Tests | Anti-Bacterial Agents - therapeutic use | Community-Acquired Infections - drug therapy | Female | Retrospective Studies | Staphylococcal Infections - microbiology | Escherichia coli - growth & development | Cross Infection - epidemiology | Medication Errors | Staphylococcal Infections - drug therapy | Staphylococcus aureus - isolation & purification | Bacteremia - drug therapy | Gram-Negative Bacterial Infections - drug therapy | Pseudomonas aeruginosa - drug effects | Cross Infection - drug therapy | Staphylococcal Infections - epidemiology | Escherichia coli - isolation & purification | Cross Infection - microbiology | Gram-Negative Bacterial Infections - epidemiology | Bacteremia - epidemiology | Aged | Staphylococcus aureus - drug effects | Staphylococcus aureus - growth & development | Community-Acquired Infections - microbiology | Health care | Therapy | Pediatrics | Communities | Physicians | Infections | Drug resistance | Epidemiology | Antiinfectives and antibacterials | Risk factors | Data dictionaries | 21st century | E coli | Trends | Nosocomial infections | Medical personnel | Pathogens | Coagulase | Comorbidity | Mortality | Staphylococcus infections | Antimicrobial agents | Risk analysis | Patients | Disease control | Studies | Infectious diseases | Hospitals | Endocarditis
Journal Article
Clinical infectious diseases, ISSN 1537-6591, 2010, Volume 51, Issue S2, pp. S183 - S197
...) has undergone rapid evolutionary changes and epidemiologic expansion to become a major cause of nosocomial and community-acquired infections worldwide... 
Osteomyelitis | Infectious diseases | Antibiotics | Antimicrobials | Endocarditis | Abscesses | Methicillin resistant staphylococcus aureus | Infections | Staphylococcus aureus | Bacteremia | HEALTH-CARE SETTINGS | INFECTIOUS DISEASES | ANTIMICROBIAL THERAPY | LINEZOLID PNU-100766 | TRANSESOPHAGEAL ECHOCARDIOGRAPHY | CLINDAMYCIN TREATMENT | MICROBIOLOGY | IMMUNOLOGY | INTRANASAL MUPIROCIN | COMPLICATED SKIN | 2 DOUBLE-BLIND | SKIN-STRUCTURE INFECTIONS | NOSOCOMIAL PNEUMONIA | Community-Acquired Infections - diagnosis | Staphylococcal Infections - pathology | Humans | Osteomyelitis - drug therapy | Bacteremia - microbiology | Anti-Bacterial Agents - therapeutic use | Methicillin-Resistant Staphylococcus aureus - pathogenicity | Cross Infection - pathology | Endocarditis, Bacterial - pathology | Community-Acquired Infections - drug therapy | Osteomyelitis - pathology | Endocarditis, Bacterial - microbiology | Staphylococcal Infections - microbiology | Endocarditis, Bacterial - drug therapy | Staphylococcal Infections - drug therapy | Bacteremia - drug therapy | Endocarditis, Bacterial - diagnosis | Bacteremia - diagnosis | Cross Infection - drug therapy | Staphylococcal Infections - diagnosis | Osteomyelitis - diagnosis | Community-Acquired Infections - pathology | Osteomyelitis - microbiology | Cross Infection - microbiology | Cross Infection - diagnosis | Methicillin-Resistant Staphylococcus aureus - isolation & purification | Bacteremia - pathology | Community-Acquired Infections - microbiology
Journal Article
Journal of Clinical Microbiology, ISSN 0095-1137, 06/2007, Volume 45, Issue 6, pp. 1705 - 1711
Article Usage Stats Services JCM Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley... 
STRAINS | RISK-FACTORS | PANTON-VALENTINE LEUKOCIDIN | NARCOTIC ADDICTS | BACTEREMIA | GENES | MICROBIOLOGY | SKIN | PNEUMONIA | DETROIT-MEDICAL-CENTER | CHILDREN | Prevalence | Community-Acquired Infections - epidemiology | Humans | Middle Aged | Male | Methicillin - pharmacology | Case-Control Studies | Bacteremia - microbiology | Microbial Sensitivity Tests | Respiratory Tract Infections - microbiology | Anti-Bacterial Agents - therapeutic use | Staphylococcal Skin Infections - drug therapy | Community-Acquired Infections - drug therapy | Female | Soft Tissue Infections - drug therapy | Staphylococcal Infections - microbiology | Methicillin Resistance | Staphylococcus aureus - genetics | Staphylococcal Infections - drug therapy | Staphylococcal Skin Infections - epidemiology | Risk Factors | Bacteremia - drug therapy | Respiratory Tract Infections - drug therapy | Treatment Outcome | Soft Tissue Infections - epidemiology | Soft Tissue Infections - microbiology | Staphylococcal Infections - epidemiology | Molecular Epidemiology | Staphylococcus aureus - classification | Bacteremia - epidemiology | Anti-Bacterial Agents - pharmacology | Respiratory Tract Infections - epidemiology | Staphylococcus aureus - drug effects | Community-Acquired Infections - microbiology | Staphylococcal Skin Infections - microbiology | Epidemiology
Journal Article
Annals of emergency medicine, ISSN 0196-0644, 2008, Volume 51, Issue 3, pp. 291 - 298
Journal Article
Infection control and hospital epidemiology, ISSN 0899-823X, 10/2008, Volume 29, Issue 10, pp. 901 - 913
Monitoring multidrug-resistant organisms (MDROs) and the infections they cause in a healthcare setting is important to detect newly emerging antimicrobial... 
Recommendations | Patient medical history | Microbial colonization | Microbial sensitivity tests | Surveillance | SHEA/HICPAC Position Paper | Hospital admissions | Health care industry | Infections | Health care facilities | Patient surveillance | ACINETOBACTER-BAUMANNII | INFECTIOUS DISEASES | PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH | ACTIVE SURVEILLANCE | PSEUDOMONAS-AERUGINOSA | HOSPITAL-ACQUIRED INFECTIONS | ESCHERICHIA-COLI | STAPHYLOCOCCUS-AUREUS INFECTION | COLONIZATION PRESSURE | ANTIMICROBIAL RESISTANCE | BLOOD-STREAM INFECTIONS | NOSOCOMIAL INFECTIONS | Carrier State - epidemiology | Prevalence | Humans | Carrier State - microbiology | Incidence | Gram-Negative Bacterial Infections - microbiology | Drug Resistance, Multiple, Bacterial | Gram-Positive Bacterial Infections - microbiology | Staphylococcal Infections - microbiology | Methicillin Resistance | Population Surveillance - methods | Cross Infection - epidemiology | Staphylococcal Infections - drug therapy | Vancomycin Resistance | Gram-Negative Bacterial Infections - drug therapy | Cross Infection - drug therapy | Gram-Positive Bacterial Infections - epidemiology | Gram-Negative Bacteria - drug effects | Staphylococcal Infections - epidemiology | Cross Infection - microbiology | Carrier State - drug therapy | Gram-Negative Bacterial Infections - epidemiology | Enterococcus - drug effects | Gram-Positive Bacterial Infections - drug therapy | Staphylococcus aureus - drug effects
Journal Article
Current Opinion in Microbiology, ISSN 1369-5274, 2007, Volume 10, Issue 5, pp. 436 - 440
Journal Article
Journal of Critical Care, ISSN 0883-9441, 2016, Volume 34, pp. 116 - 120
Abstract Introduction Infection is a major determinant of clinical outcome among patients in intensive care unit (ICU... 
Critical Care | Nosocomial infection | ICU | Antimicrobial resistance | Nigeria | MORTALITY | FLUOROQUINOLONE USE | SUSCEPTIBILITY | PREVALENCE | ACQUIRED INFECTION | GRAM-NEGATIVE BACTEREMIA | SURVEILLANCE | UNIVERSITY | EPIDEMIOLOGY | PATHOGENS | CRITICAL CARE MEDICINE | Klebsiella pneumoniae - isolation & purification | Staphylococcus aureus - physiology | Humans | Middle Aged | Drug Resistance, Bacterial | Male | Bacteremia - microbiology | Microbial Sensitivity Tests | Young Adult | Anti-Bacterial Agents - therapeutic use | Surgical Wound Infection - drug therapy | Klebsiella pneumoniae - physiology | Adult | Female | Urinary Tract Infections - microbiology | Retrospective Studies | Staphylococcal Infections - microbiology | Escherichia coli - physiology | Cloxacillin - therapeutic use | Thienamycins - therapeutic use | Escherichia coli Infections - drug therapy | Intensive Care Units | Pneumonia, Bacterial - microbiology | Staphylococcal Infections - drug therapy | Klebsiella Infections - drug therapy | Tertiary Care Centers | Staphylococcus aureus - isolation & purification | Bacteremia - drug therapy | Escherichia coli Infections - microbiology | Trimethoprim, Sulfamethoxazole Drug Combination - therapeutic use | Klebsiella Infections - microbiology | Cross Infection - drug therapy | Urinary Tract Infections - drug therapy | Catheter-Related Infections - drug therapy | Ceftriaxone - therapeutic use | Escherichia coli - isolation & purification | Catheter-Related Infections - microbiology | Cross Infection - microbiology | Pneumonia, Bacterial - drug therapy | Surgical Wound Infection - microbiology
Journal Article